Norflex
Loading...Norflex Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Some patients may experience transient episodes of light-headedness, dizziness or syncope. Norflex may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.
Norflex Injection contains sodium bisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than nonasthmatic people.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Orphenadrine citrate is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo skeletal conditions.
History
There is currently no drug history available for this drug.
Other Information
Orphenadrine citrate is the citrate salt of orphenadrine (2-dimethylaminoethyl 2- methylbenzhydryl ether citrate). It occurs as a white, crystalline powder having a bitter taste. It is practically odorless; sparingly soluble in water, slightly soluble in alcohol.
Each Norflex Extended-release Tablet contains 100 mg orphenadrine citrate. Norflex Extended-release Tablets also contain: calcium stearate, ethylcellulose, and lactose. Norflex Injection contains 60 mg of orphenadrine citrate in aqueous solution in each ampul. Norflex Injection also contains: sodium bisulfite NF, 2.0 mg; sodium chloride USP, 5.8 mg; sodium hydroxide, to adjust pH; and water for injection USP, q.s. to 2 mL.
Sources
Norflex Manufacturers
-
3m Pharmaceuticals
![Norflex (Orphenadrine Citrate) Tablet, Extended Release Norflex (Orphenadrine Citrate) Injection [3m Pharmaceuticals]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Norflex | 3m Pharmaceuticals
TABLETS: Adults – Two tablets per day; one in the morning and one in the evening.
INJECTION: Adults – One 2 mL ampul (60 mg) intravenously or intramuscularly; may be repeated every 12 hours. Relief may be maintained by 1 Norflex Extended-release Tablet twice daily.
-
Graceway Pharmaceuticals, Llc
Norflex | Graceway Pharmaceuticals, Llc
INJECTION: Adults - One 2 mL ampul (60 mg) intravenously or intramuscularly; may be repeated every 12 hours.
Login To Your Free Account